Sortis

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sortis

Quick Facts: Sortis (Atorvastatin)

Property Description
Active Ingredient Atorvastatin calcium
Form Film-coated tablets (Oral)
Pharmacological Class Statin (HMG-CoA reductase inhibitor)
General Use Managing high cholesterol and dyslipidemia
Origin Synthetic compound

What Type of Medicine is Sortis? Defining Atorvastatin

Sortis is a synthetic, prescription-only medicine that contains the active ingredient Atorvastatin. It is categorized pharmacologically as a statin, which is the common term for a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. This classification is critical because it identifies the medication as a targeted therapeutic agent for chronic lipid management. Atorvastatin is used to help lower cholesterol and triglycerides in the blood. Atorvastatin is clinically recognized for its efficacy in lipid modification, positioning it as a cornerstone drug for adults requiring long-term control of high cholesterol levels.

Composition and Pharmaceutical Form: Oral Film-Coated Tablets

The foundation of Sortis is the active substance, Atorvastatin calcium, which is provided as a single active ingredient product. This composition is presented in the final pharmaceutical form of an oral, film-coated tablet. As an oral medication, it is designed for systemic delivery following ingestion. The film-coated presentation is a standard pharmaceutical feature ensuring consistent bioavailability of the active component, while the specific formulation ensures the reliable release of Atorvastatin within the digestive system.

The General Purpose of Sortis: Managing Lipid Levels

The primary general purpose of Sortis is the management of dyslipidemia, which refers to abnormal concentrations of fats in the blood, particularly high levels of low-density lipoprotein cholesterol (LDL-C). By inhibiting the rate-limiting enzyme in the hepatic cholesterol synthesis pathway, Atorvastatin effectively drives down the concentration of "bad cholesterol." This function is applied in a typical use scenario where a patient requires sustained reduction of circulating lipids to mitigate the long-term risks associated with excessive fat accumulation in the vascular system.

Regulatory References

  1. NIH StatPearls Atorvastatin
  2. MedlinePlus Atorvastatin Drug Information

What side effects are possible with Sortis?

Possible side effects and safety information

The safety profile of Sortis (Atorvastatin) is formally classified by regulatory authorities based on the incidence and type of possible adverse reactions observed during clinical trials and post-marketing surveillance.

Adverse Reaction Scope

Category Regulatory Documentation Overview
Common Adverse Reactions Frequent effects typically include Nasopharyngitis (common cold symptoms), Arthralgia (joint pain), Myalgia (muscle pain), Diarrhea, and Headache. Increased levels of liver function tests and blood creatine kinase are also common regulatory findings.
Serious Adverse Reactions Officially designated rare but severe risks include Rhabdomyolysis (severe muscle breakdown), Myopathy, and Hepatic Failure. Hypersensitivity reactions, including Anaphylaxis and severe skin conditions, are also documented as very rare or rare.
System-Organ Classes Adverse effects are grouped into categories such as Musculoskeletal and connective tissue disorders, Gastrointestinal disorders, Nervous system disorders, and Hepatobiliary disorders.

Safety Constraints and Special Populations

Specific limitations and patient factors are explicitly stated in official labeling. The medicine is contraindicated in individuals with active liver disease or unexplained persistent elevations of hepatic transaminases. It is also contraindicated during pregnancy and lactation. Advanced age (over 65 years), uncontrolled hypothyroidism, and renal impairment are recognized as factors that may increase the risk of muscle-related adverse reactions.

Regulatory Safety Summary

The regulatory structure formally defines the spectrum of risks, from common, non-serious effects to rare, serious conditions like liver failure. The labeling requires consideration of predisposing factors for muscle injury and mandates monitoring of liver function tests, establishing clear constraints on its use in specific clinical contexts.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that no specific antidote is available for an overdose with Sortis (Atorvastatin), and management must be entirely symptomatic and supportive. Due to the drug's extensive protein binding, hemodialysis is not expected to significantly enhance its clearance from the body.

Overexposure is formally associated with the risk of severe tissue toxicity, manifesting primarily as Myopathy (unexplained muscle pain, tenderness, or weakness) and elevated Creatine Kinase (CK) levels. The most severe outcomes documented in regulatory sources include Rhabdomyolysis, which can lead to Acute Renal Failure, and rare reports of Fatal and Non-Fatal Hepatic Failure.

Immediate medical attention is mandated if any signs of these severe events are observed. Urgent action is required for symptoms such as unexplained muscle pain, malaise, or fever. Atorvastatin must be discontinued immediately if myopathy is suspected or confirmed by markedly elevated CK levels. Regulatory documents also note that advanced age (65 years or greater) and underlying renal impairment are documented factors that increase the risk for these severe overdose-related complications.

Therapeutic Uses of Sortis

What Sortis Treats: Main Uses and Benefits

Sortis (Atorvastatin) is generally used for managing specific metabolic conditions that create a high degree of physiological strain on long-term cardiovascular health. The medicine is commonly used to help with lipid management, including lowering LDL-C and triglyceride levels. Its therapeutic focus is applied in addressing underlying risks that are often asymptomatic until a major event occurs.


The medicine contributes to easing the overall symptom load associated with chronic lipid abnormalities, including Primary Hyperlipidemia, Mixed Dyslipidemia, and the Familial Hypercholesterolemias. It is considered relevant in clinical settings for patients categorized as having a moderate or high risk of experiencing a major vascular event, with the primary goal being is used for managing the probability of a heart attack and ischemic stroke.

“The supportive relief provided may help patients cope more steadily with symptom fluctuations and is relevant when supportive symptom management is appropriate.”

Applied during phases where the patient requires long-term protection, this intervention generally may assist with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities. It is commonly used across conditions characterized by periods of heightened symptoms (risk), such as in patients with established Coronary Heart Disease and those with Type 2 Diabetes Mellitus who have multiple risk factors.


Quick Fact: Relief for Asymptomatic Metabolic Strain

Focus Therapeutic Use Context Benefit
Symptom Cluster Elevated LDL-C and Triglycerides (Asymptomatic Risk) Helps address symptom clusters related to systemic imbalance
Condition Category Dyslipidemia and Hypercholesterolemia Used in situations involving certain distressing symptoms (future events)
Clinical Scenario Primary and Secondary Prevention Contributes to improved comfort and health stability long-term

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Sortis (Atorvastatin)

Sortis (Atorvastatin) use is strictly defined by regulatory eligibility rules based on age, physiological state, and existing medical conditions.

Contraindicated Populations (Must Not Use)

Classification Population/Condition
Absolute Active liver disease, including persistent unexplained elevations of liver enzymes.
Absolute Pregnancy and Lactation (Breastfeeding).
Absolute Hypersensitivity to atorvastatin or any component of the medication.
Contraception Women of child-bearing potential not using reliable contraception.

Restricted and Eligible Populations

Adult patients are the standard eligible population. Use in children and adolescents is only established for patients aged 10 years and older for specific high-cholesterol conditions. The use is not generally established in children under 10 years of age.

Eligibility also requires caution for individuals with certain risk factors for muscle damage (myopathy), such as advanced age (65 years and older) and uncontrolled hypothyroidism. Temporary discontinuation is required during acute, serious conditions like major surgery or severe trauma. While dose adjustment is not required for renal impairment, active liver disease remains an absolute contraindication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sortis (Atorvastatin) interactions are officially documented, primarily involving changes in the drug's plasma concentration due to metabolic and transporter effects, or an increased risk of muscle toxicity.

Interacting Agents and Constraints

Classification Detail Description
Exposure-Increasing Agents Strong inhibitors of the CYP3A4 enzyme and hepatic uptake/efflux transporters (OATP1B1, BCRP, P-gp) increase Atorvastatin levels. Examples include Cyclosporine, Itraconazole, and certain antiviral medications.
Risk of Muscle Toxicity Pharmacodynamic interactions with Fibrates (e.g., Gemfibrozil), Colchicine, and Lipid-Modifying Doses of Niacin (ge 1 g/day) are documented to increase the official risk of myopathy and rhabdomyolysis.
Food and Herbal Products Consumption of large quantities of grapefruit juice (e.g., ge 1.2 liters per day) is officially restricted as it can increase the drug’s plasma concentration. St. John’s Wort may reduce concentrations.
Administration Timing Rule To manage concentration reduction caused by dual-acting substances like Rifampin, the official label requires that Atorvastatin be co-administered simultaneously.
Effect on Other Drugs Atorvastatin may formally increase the plasma levels of co-administered Oral Contraceptives (containing norethindrone and ethinyl estradiol) and Digoxin.

The profile is further structured by official regulatory warnings that the overall interaction risk, particularly for muscle-related effects, is recognized as being increased by predisposing factors such as advanced age (ge 65 years) and renal impairment.

Mechanism of Action

Blocking the Cholesterol Production Pathway

The primary mechanism of Sortis involves acting as a selective, competitive inhibitor of the enzyme HMG-CoA reductase in the liver. This molecular interaction halts the mevalonate pathway, the fundamental cascade responsible for the internal, endogenous synthesis of cholesterol. By reducing the pool of free sterols within liver cells, this inhibition triggers a pronounced compensatory signaling response throughout the entire lipid system.

Enhancing Systemic Lipoprotein Clearance

The drug’s molecular action causes the liver to activate SREBP signaling, which increases the surface expression of LDL receptors. This resulting high density of receptors acts as an accelerated catabolic system, rapidly extracting LDL-C and other atherogenic lipoproteins from the systemic circulation. This sequence of enhanced clearance is the primary physiological consequence of the enzyme inhibition and receptor upregulation.

Modulating Vascular and Inflammatory Systems

Beyond its primary lipid-lowering cascade, Atorvastatin also engages in pleiotropic effects by reducing the downstream synthesis of non-sterol intermediates, such as isoprenoids. By modulating these products, the drug modulates the function of the vascular endothelium and reduces localized inflammatory signaling within the blood vessel environment. These modulations provide secondary physiological effects independent of plasma lipid concentration.

Dosage and Administration Information

How to Use Sortis: Official Administration Guidelines

Sortis (atorvastatin) is administered as an oral film-coated tablet intended for long-term use as an adjunct to diet and other non-pharmacological measures. The administration is highly standardized across all approved uses, focusing on simple daily adherence and measured dose adjustments over time.


Administration Scope and Dosage

Entity Official Instruction
Route of Administration Oral
Frequency and Timing Once daily; may be taken at any time of day, with or without food.
Standard Adult Dose Starting Dose: 10 mg or 20 mg once daily. Maximum Dose: 80 mg once daily.
Dose Titration Interval Dosage adjustments, if required, should be made only after an interval of 4 weeks or more.
Missed Dose Rule If a dose is missed, the patient should proceed to take the next scheduled dose at the usual time; do not double the dose.

Procedural and Population Rules

The tablet must be swallowed whole to maintain its intended integrity. Dosing protocols include specific limits for particular patient groups and usage contexts. For instance, no dosage adjustment is required for patients with renal impairment. In pediatric patients aged 10 years and older with Heterozygous Familial Hypercholesterolemia, the maximum recommended daily dose is restricted to 20 mg. Furthermore, the dosage must be specifically limited when Sortis is co-administered with certain other medications, such as clarithromycin. These explicit rules define the structured approach to therapy and ensure procedural accuracy.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Sortis (Atorvastatin)


Evidence for Use in Preventing Recurrent Heart Events (Secondary Prevention)

Clinical evidence in this area primarily consists of large-scale, long-term Randomized Controlled Trials ( RCTs). These studies examined the medicine in adults with documented conditions like Coronary Heart Disease ( CHD) or those who had a prior heart attack or stroke. Researchers monitored outcomes that were evaluated in the study, specifically including the rates of fatal and non-fatal heart attack, stroke, and the need for revascularization procedures.

Findings describe patterns observed in these studies related to these major outcomes over the defined trial periods. The evidence contributes to the broader evidence landscape regarding outcomes in patients with documented disease. However, the follow-up durations were often limited, meaning that patterns of effect over the entire decades-long progression of atherosclerosis are not fully established.


Evidence for Use in Preventing a First Heart Event (Primary Prevention)

Studies exploring primary prevention were also designed as large RCTs and enrolled adults who had no history of heart disease but were at increased risk due to factors like high blood pressure or Type 2 Diabetes Mellitus. Research examined studies related to conditions involving periods of heightened risk before a first major event occurred.

Research highlights changes measured during the study period for both the major vascular events and the surrogate outcomes, such as LDL-C levels. Results apply only to the populations studied, which were defined as having a moderate or high estimated risk. Evidence is limited for individuals considered to be at a very low risk of an event.


Evidence for the Management of Cholesterol and Lipids

Research was evaluated in patients with conditions like Primary Hypercholesterolemia and Mixed Dyslipidemia. Studies monitored outcomes by measuring lipid biomarkers, including the percent change from baseline in LDL-C (low-density lipoprotein cholesterol) and Triglycerides. Research describes consistent patterns related to lowering lipid biomarkers across the studied dyslipidemia types. However, these findings are based on surrogate markers, not hard clinical endpoints, and data for extremely rare types of high cholesterol remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Sortis (FAQ)

Q: What is the primary purpose of taking Sortis?

A: According to regulatory documents, Sortis is prescribed to lower high cholesterol and lipid levels. Its primary objective is to reduce the risk of serious cardiovascular events, such as heart attack and stroke, in patients who are considered to be at risk.

Q: Is Sortis used only for high cholesterol, or does it treat other heart conditions?

A: Sortis is indicated for lowering cholesterol, but official labels state it is also used to reduce the risk of specific cardiovascular events. This includes non-fatal heart attack, stroke, and the need for revascularization procedures in individuals with certain risk factors.

Q: Why is Sortis sometimes prescribed even when a person's cholesterol levels are already normal?

A: Sortis may be prescribed to reduce the overall cardiovascular risk even in individuals whose cholesterol levels are within the normal range. This is often the case for patients who have other specific risk factors, such as diabetes or a family history of heart disease.

Q: How long does it typically take to see the effects of Sortis on cholesterol test results?

A: Official prescribing information indicates that lipid levels are typically monitored and any necessary dosage adjustments are made within 2 to 4 weeks after starting Sortis therapy or changing the dose. This time frame allows healthcare providers to assess the response to therapy.

Q: Why don't people who take Sortis always feel different once it starts working?

A: Sortis treats chronic conditions like high cholesterol, which often cause no noticeable symptoms in patients. Because of this asymptomatic nature, you may not notice any immediate change in how you feel while the medicine is actively working to lower your lipid levels.

Q: What might happen if someone were to temporarily stop taking Sortis?

A: Regulatory-linked sources suggest that stopping Sortis may lead to a rebound effect. This means your cholesterol levels could return to pre-treatment levels within a few weeks, which may, in turn, increase your overall risk of cardiovascular events like heart attack and stroke.

Q: What are the general expectations for taking Sortis over the long term (many years)?

A: Sortis is generally intended for long-term use as part of a chronic care strategy for managing lipid levels. The continued benefit of the drug is typically obtained by maintaining therapy consistently.

Q: What is the difference between the 'bad' cholesterol (LDL) and the 'good' cholesterol (HDL) when taking Sortis?

A: Sortis works primarily by lowering LDL-C (Low-Density Lipoprotein Cholesterol), which is commonly referred to as 'bad' cholesterol. The drug can also decrease triglycerides and cause modest increases in HDL-C (High-Density Lipoprotein Cholesterol), or 'good' cholesterol.

Q: Are there any specific lifestyle or dietary restrictions that must be followed while on Sortis?

A: Official information describes Sortis as an adjunct to a cholesterol-lowering diet, and adherence to diet, exercise, and weight control is described as part of the complete treatment program. Consumption of large quantities of grapefruit juice is also restricted due to potential interaction.

Q: What is the recommended guidance for alcohol consumption while using Sortis?

A: Official warnings state that consuming substantial quantities of alcohol may increase the risk of liver-related side effects. For this reason, limiting or avoiding alcohol use is typically advised.

Q: Does taking Sortis require special blood tests or monitoring?

A: Yes. Liver enzyme tests are typically performed before starting Sortis therapy to establish a baseline. These tests are then repeated as clinically indicated during treatment to monitor liver function.

Q: Is it true that Sortis can affect liver function?

A: Official warnings note that Sortis can cause increases in serum transaminase levels. Liver enzyme tests are typically performed before and during treatment to monitor for any changes in liver function.

Q: What are the warnings for people taking Sortis who have a history of kidney disease or thyroid problems?

A: Warnings note that both uncontrolled hypothyroidism (underactive thyroid) and renal impairment (kidney disease) are recognized risk factors. These conditions may increase the risk of developing myopathy (muscle disease) while using Sortis.

Q: Why is Sortis generally avoided during pregnancy and breastfeeding?

A: Sortis is contraindicated (should not be used) during pregnancy and breastfeeding. This is because official documents indicate a potential for fetal harm during pregnancy and state that statins are known to be excreted in breast milk.

Q: What are the potential signs of a serious side effect like rhabdomyolysis?

A: Official labels advise that patients report unexplained muscle pain, tenderness, or weakness promptly to their healthcare provider. This is especially important if these symptoms are accompanied by malaise, fever, or dark-colored urine, as these may be signs of a serious muscle condition.

Q: Are muscle aches or weakness common side effects associated with Sortis?

A: Yes, muscle and joint issues are frequently included in official adverse reaction lists. This includes muscle pain (myalgia), pain in the extremities, muscle spasms, and joint pain (arthralgia).

Q: Is it normal to experience symptoms like gas, indigestion, or diarrhea when taking Sortis?

A: Yes, common gastrointestinal adverse reactions listed in official documents include diarrhea, flatulence (gas), dyspepsia (indigestion), and abdominal pain.

Q: Can taking Sortis cause symptoms that feel like a common cold?

A: Yes, nasopharyngitis is listed as a very common side effect in official documents. This condition involves symptoms that are similar to those of a common cold, such as a runny nose, stuffy nose, or sneezing.

Q: Are joint pain and headaches frequently reported when first starting Sortis?

A: Yes, both headache and arthralgia (joint pain) are listed as common side effects of Sortis in regulatory sources.

Q: Is it a fact or a myth that statins like Sortis cause muscle damage in most people?

A: Muscle pain (myalgia) is listed as a common side effect. However, the most severe muscle issues, such as myopathy or rhabdomyolysis, are considered rare events and are not experienced by most people taking the medication.

Q: Can taking Sortis cause issues like memory loss or confusion?

A: Official FDA label information notes that generally non-serious and reversible cognitive effects, such as memory loss and confusion, have been reported rarely with statin use. These symptoms usually resolve after the drug is stopped.

Q: What is the reported connection between Sortis and a mild increase in blood sugar?

A: Official warnings state that use of Sortis has been associated with increases in blood sugar (fasting serum glucose) and HbA1c levels. Diabetes and hyperglycemia are included in the list of common adverse reactions in official documents.

How should Sortis be stored and disposed of?

How to Store and Dispose of Sortis (Atorvastatin)

Official regulatory guidelines strictly define the conditions necessary for storing and handling Sortis tablets:

  • Storage Temperature: Store the medicine at controlled room temperature, ideally between 20 C and 25 C (68 F to 77 F).
  • Environmental Protection: Keep the tablets in the original, closed container and protect them from excessive moisture and direct light. Do not freeze the medicine.
  • Child Safety: It is mandatory to keep Sortis and all medicines out of the reach of children and pets.
  • Disposal: Do not dispose of unused or expired Sortis by flushing it down a toilet or pouring it down a drain. Consult a healthcare professional or pharmacist to find a local drug take-back program or follow other official instructions for safe pharmaceutical disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sortis found in:

A-Z Index: